Compare CZFS & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZFS | XOMA |
|---|---|---|
| Founded | 1984 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 308.6M |
| IPO Year | 1995 | N/A |
| Metric | CZFS | XOMA |
|---|---|---|
| Price | $60.81 | $26.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 6.3K | ★ 118.2K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 30.26 | N/A |
| EPS | ★ 7.62 | N/A |
| Revenue | ★ $9,881,000.00 | N/A |
| Revenue This Year | N/A | $76.93 |
| Revenue Next Year | $2.64 | $29.28 |
| P/E Ratio | ★ $7.84 | $29.64 |
| Revenue Growth | ★ 2.82 | N/A |
| 52 Week Low | $49.99 | $18.40 |
| 52 Week High | $69.30 | $39.92 |
| Indicator | CZFS | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 54.11 |
| Support Level | $58.25 | $23.92 |
| Resistance Level | $63.69 | $27.68 |
| Average True Range (ATR) | 1.90 | 1.44 |
| MACD | -0.25 | 0.19 |
| Stochastic Oscillator | 17.68 | 63.39 |
Citizens Financial Services Inc is a Pennsylvania-chartered bank and trust company. The company through its banking subsidiary provides banking activities and services for individual, business, governmental and institutional customers. Its activities and services principally include checking, savings, and time deposit accounts; residential, commercial and agricultural real estate, commercial and industrial, state and political subdivision and consumer loans; and a variety of other specialized financial services. The Trust and Investment division of the Bank offers a full range of client investment, estate, mineral management, and retirement services.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.